Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Results depend on baseline status, dose, route, sleep, nutrition, and program design
Arcutis disclosed aggregated results from the Phase III INTEGUMENT-1 and INTEGUMENT-2 trials in January 2024, revealing that 91.5% of atopic dermatitis patients treated with the drug showed measurable improvement in the Eczema Area and Severity Index (EASI) score after four weeks
BPC-157 4.2 out of 5 CAD $85.00 A synthetic 15-amino-acid sequence derived from human gastric juice, BPC-157 is supplied lyophilized for in vitro tissue-protection and angiogenesis research
Front Bioeng Biotechnol 11
The CXCR4-CXCL12 axis is instrumental in orchestrating the positioning of PC within the splenic red pulp and their deposition in BM
J., Martinez, C., Lai, X., Zhou, J
US$ 23.50
US$ 26.34
US$ 28.79
US$ 21.99
US$ 26.76
